Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by carduon Feb 24, 2011 3:55pm

268 Views

Post# 18189560

RE: RE: Anybody know when a phase III trial is exp

" I'm beginning to wonder why the company isn't advancing this product to the final stage of clinical trials. "

Your points are very well taken. It may be that BT has a "vision" regarding the development of this treatment, a vision he won't share with the rest of us plebeians.

Be careful how you talk about BT. Your honest opinion, as you see it, could be construed as "whining" by a certain member of this board. That attitude = arrogance, in my honest opinion.

Bullboard Posts

Rising miner increases graphite price, restarts Québec mill